Compositions for Sustained Release of a Carbonic Anhydrase Inhibitor (CAI) from Biodegradable Polymeric Microparticles

Case ID:
C13930
Disclosure Date:
12/4/2015
Description:
Glaucoma is a leading cause of irreversible blindness that affects over 60 million people worldwide.  Traditional therapies aim to reduce intraocular pressure and include topical eye drop formulations, laser treatments, and incisional surgeries. Eye drop treatment is effective, but limited by drop toxicity, poor bioavailability of medication, and poor patient adherence.  Johns Hopkins inventors have developed a novel sustained delivery system for CAI for the treatment of glaucoma.
Patent Information:
Inventors:
Category(s):
For Information, Contact:
Sonriza Ford
sford23@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum